Sign in
Taking people in United StatesPhase 2

SAMe supplement for people with alcoholic cirrhosis of the liver

Tests SAMe against placebo for liver function in people with alcoholic cirrhosis.

Key facts

Who runs it
Indiana University
Where
Indianapolis and Los Angeles, United StatesSee the 2 sites
Trial code
Registry title
SAMe Trial for Patients With Alcoholic Cirrhosis
Status
Recruiting
Phase
Phase 2
People taking part
196 people, planned
Started
22 Oct 2020
Expected to end
1 Mar 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo
  • SAMe 400 mg tablet
Record updated
31 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with alcohol-related cirrhosis (scarring of the liver), Child Class A or B, to test SAMe against placebo. Healthy people who drink little or no alcohol can also join as a control group.

Age
18 to 70 years
Sex
All sexes
Disease stage
Cirrhosis caused by alcohol, Child Class A or B at enrolment. Cirrhosis shown by clinical signs, Fibroscan®, CT, MRI or biopsy. Patients may or may not drink alcohol during the study.
Earlier treatment
No other investigational drug, biologic or medical device trial within 30 days before screening.

Main reasons for not taking part

  • Active infection, or known hepatitis C, hepatitis B or HIV
  • Gut bleeding within the prior 28 days, or liver cancer (hepatocellular carcinoma) now or in the past
  • Serious illness such as COPD, heart failure or kidney failure, or a weakened immune system
  • Pregnant, may become pregnant, or breastfeeding
  • Psychiatric illness such as bipolar disorder, gastric bypass surgery, or a family member already in the study

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Evidence of cirrhosis as per clinical signs and/or noninvasive transient elastography (Fibroscan®), computed tomography, magnetic resonance imaging including MRI elastography compatible with cirrhosis and/or histopathology by biopsy and
  • subjects with clinical presentation either in Child Class A or B at the time of enrollment
  • individuals 18 to 70 years old and may or may not consume alcohol during study
  • ) individuals 18 to 70 years old (2) able to provide informed consent (3) subjects do not consume any alcohol or those who drink < 50 grams per day on average in women and < 80 grams per day on average in men (4) subjects are healthy without underlying acute or chronic medical conditions

Who cannot take part

  • Gastrointestinal bleeding within the prior 28 days3
  • Participation in another investigational drug, biologic, or medical device trial within 30 days prior to screening
  • consume any alcohol within 3 months before the study
  • Active infection as evidenced by positive urine culture, blood culture, or pneumonia,
  • Known co-existing infection with hepatitis C, hepatitis B, or HIV
  • Significant systemic or major illness including chronic obstructive pulmonary disease, congestive heart failure, and renal failure that in the opinion of the Investigator would preclude the patient from participating in and completing the study
  • Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of SAMe such as those with gastric bypass surgery
  • Subjects with history of/diagnosis of hepatocellular carcinoma
  • Subjects with psychiatric illnesses such as bipolar disorders as SAMe may interfere with the levels of anti-psychotic drugs and
  • subjects with an active and serious medical disease
  • subjects with an infectious disease
  • subjects with localized or systemic infection
  • Women who are pregnant, may become pregnant, or nursing
  • Members from the same family of study participant. This is based on the recent paper on the non-random sampling in randomized controlled trials4. We acknowledge that if we assign family members to identical treatment, randomization would not be totally correct; but if properly randomized, there is a chance that the members of the family might mix the pills. To avoid this issue and maintain the integrity of randomized blinded fashion, we will not include members from the same family into the study
  • Subjects who are immunocompromised

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • Indiana University HospitalIndianapolis, United StatesContact: Maggie Hesler, B.STaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Brandon LoveTaking people

About the trial

What the trial wants to find out

The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary objective of the study is to test relationship between SAMe (S-adenosylmethionine) supplement on liver function. The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.

The 3 groups in the trial

  • PlaceboPlacebo, for comparison

    Alcoholic Cirrhosis on placebo

  • 1,200 mg SAMeTreatment being tested

    SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months

    Treatment: SAMe 400 mg tablet

  • Non-drinking ControlsNo study treatment, for comparison

    Non-drinking healthy controls

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis
Plain-language title
SAMe supplement for people with alcoholic cirrhosis of the liverGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT04250259, who can take part
Record updated
31 March 2026